Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a Study of mRNA-Based Multivalent Seasonal Influenza Vaccine Candidates in Adults
NCT07204964Phase 2Completed
- Sponsor
- GSK
- Start
- Oct 2025
- Primary completion
- Aug 2026
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in influenza (10 arms), sponsored by GSK. Primary endpoints: Geometric Mean Titer of Antigen 1 Titer at Day 29, Geometric Mean Increase of Antigen 1 Titer at Day 29 and 9 more. Started Oct 2025; status: completed.
02
Conditions
influenza
Beyond the preview
Go deeper on NCT07204964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07204964.